Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BMY

Try These 3 Stocks Ideas for a Golden Retirement

The U.S. market came back in July and early August owing to a robust job market, strong corporate earnings, and a slight decline in inflation. However, the Fed’s hawkish stance to hike the interest rates aggressively until inflation comes down to the target level is expected to keep the market…

StockNews.com

What Are Whales Doing With Bristol-Myers Squibb

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

2 Pharma Stocks That'll Make You Rich in the Long Term

Substantial investments in R&D, an aging population, and growing demand for advanced drugs to treat chronic diseases should drive the pharmaceutical industry’s growth. Therefore, investing in fundamentally strong and dividend-paying pharma stocks Johnson & Johnson (JNJ) and Bristol-Myers Squibb (BMY) could help dodge the current market volatility and generate substantial…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Income Stocks to Turn to When Times Are Tough

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

StockNews.com

Looking At Bristol-Myers Squibb's Recent Whale Trades

Benzinga

5 Value Stocks to Buy Ahead of the Fall Season

The stock market has witnessed a rough ride amid macroeconomic headwinds this year. Despite the GDP decline for two consecutive quarters, economists believe the economy is far from recession. Here are five fundamentally solid value stocks AstroNova (ALOT), Bristol-Myers Squibb (BMY), Bluegreen Vacations (BVH), GSK (GSK), and Honda Motor (HMC),…

StockNews.com

3 High-Yield Dividend Stocks to Help You Beat Stagflation

With the Fed committed to its rate hikes to bring down inflation, employment staggering, and prices refusing to come down, stagflation might be around the corner. We believe these high-yield dividend stocks Natural Resource(NRP), Kronos Worldwide(KRO), and Bristol-Myers Squibb(BMY) might help one beat the stagflation. Read more….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Bristol-Myers Squibb Whale Trades For July 12

Benzinga

Is Biotech Ready for Another Bull Run? 3 Stocks to Get in Ahead of the Crowd

The biotech industry flourished during the height of the COVID-19 pandemic and reported record revenues and earnings last year. Despite the market slowdown, the sector is poised for another bull run, given the continued global fight against COVID-19 and the increasing demand with an aging population. Popular biotech stocks Pfizer…

StockNews.com

3 Cheap Large-Cap Stocks Still Beating the Market

With job growth remaining strong in June, the Fed is expected to raise interest rates aggressively. Therefore, the stock market may witness further downside. Amid this backdrop, it could be wise to invest in large-cap stocks Bristol-Myers Squibb (BMY), Bayer (BAYRY), and Mitsubishi Heavy Industries (MHVYF), which have shown resilience…

StockNews.com

5 Buy-Rated Healthcare Stocks Trading at a Discount

Inelastic demand, growing investments, and impressive breakthroughs should help the healthcare sector survive the potential recession. This is why we believe quality healthcare stocks Assertio (ASRT), Bayer (BAYRY), Bristol-Myers Squibb (BMY), Catalyst Pharmaceuticals (CPRX), and Ipsen (IPSEY), which are currently trading at discounts to their peers, could be solid investments…

StockNews.com

Scoop up These 5 Dividend Stocks on Sale

The Federal Reserve’s aggressive interest hikes have fostered recession fears and significant volatility in the stock market. So, investors can consider adding quality dividend stocks Embotelladora Andina (AKO.B), Bristol-Myers Squibb (BMY), Bayer Aktiengesellschaft (BAYRY), A.P. Møller - Mærsk A/S (AMKBY), and Honda Motor (HMC) to their portfolios to ensure a…

StockNews.com

Bristol-Myers Squibb Whale Trades For July 07

Benzinga

This Is What Whales Are Betting On Bristol-Myers Squibb

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 12 strange trades.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

New York Judge Denies Bristol Myers Claim To Dismiss Lawsuit Over Delayed Cancer Drug Approval: Reuters

According to a Reuters report, U.S. District Judge Jesse Furman in Manhattan refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co (NYSE:BMY) of delaying its Breyanzi cancer drug to avoid payments to former Celgene shareholders. The judge rejected Bristol Myers' claim that it was never properly notified about its alleged default…

Benzinga

This Is What Whales Are Betting On Bristol-Myers Squibb

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

StockNews.com

3 Drug Manufacturers to Buy on the Pullback

The global pharmaceutical industry is expected to thrive with the lingering impact of COVID-19 and the evolving healthcare landscape. Given the industry’s solid prospects, the pullbacks in drug manufacturing stocks Merck & Co (MRK), Bristol-Myers Squibb (BMY), and Bayer Aktiengesellschaft (BAYRY) amid the broader market correction preset solid buying opportunity.…

Benzinga

Looking At Bristol-Myers Squibb's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 11 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Bristol-Myers Squibb Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 25 strange trades.

StockNews.com

3 Red-Hot Healthcare Stocks Ignoring the Market's Downtrend

Despite bearish market sentiment, the healthcare industry has outperformed the broader market thanks to its defensive nature. Given overwhelming demand and the need for global healthcare development, we think the stocks of quality healthcare companies Cigna (CI), Organon (OGN), and Bristol-Myers Squibb (BMY) could be solid bets now. These stocks…

Benzinga

Bristol-Myers Squibb Whale Trades Spotted

StockNews.com

3 Pharmaceutical Stocks That Look Like Huge Bargains

Increasing investments in R&D and rising expenditure on healthcare are expected to bolster the pharmaceutical sector's growth. Therefore, we think the stocks of fundamentally sound pharmaceutical companies Bristol-Myers Squibb (BMY), Bayer Aktiengesellschaft (BAYRY), and Catalyst Pharmaceuticals, Inc. (CPRX), which are currently trading at huge discounts to their peers, could be…

Benzinga

Looking At Bristol-Myers Squibb's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 14 strange trades.

Benzinga

Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer

Bristol Myers Squibb & Co's (NYSE:BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in urothelial carcinoma did not meet the primary endpoint of overall survival (OS) at the final analysis. The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma…

Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.